法布雷病心血管表现的特异性治疗:系统综述
该系统综述纳入72项研究,评估酶替代治疗和伴侣蛋白治疗对法布雷病心血管表现的有效性。随机研究偏倚风险不高,但非随机研究偏倚风险严重,研究间异质性大,难以评估疗效。目前尚不明确特异性治疗是否充分影响法布雷病的心血管表现,需更大规模且标准化的研究进一步阐明。
要点
- 特异性治疗对法布雷病心血管表现的疗效尚不明确。
- 随机研究偏倚风险不高,但非随机研究偏倚风险严重。
- 研究异质性大,需标准化结局和更大样本进一步验证。
核心结论
- 尚不明确特异性治疗是否充分影响法布雷病的心血管表现。
研究设计与样本
- 系统综述纳入72项研究,包括7项随机干预研究、16项有对照组的非随机干预研究和49项无对照组的非随机干预研究。
主要发现
- 随机研究未处于严重偏倚风险,但其他研究处于严重偏倚风险。
- 研究在设计、结局测量和发现方面高度异质,难以评估特异性治疗的疗效。
局限性
- 非随机研究偏倚风险严重,研究间高度异质,难以评估疗效。
- 需要更大规模、采用标准化临床和表型结局(使用现代技术测量)的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The cardiovascular manifestations of Fabry disease are common and represent the leading cause of death. Disease-specific therapy, including enzyme replacement therapy (ERT) and chaperone therapy (migalastat), is recommended for patients exhibiting cardiovascular involvement, but its efficacy for modulating cardiovascular disease expression and optimal timing of initiation remains to be fully established. We therefore aimed to systematically review and evaluate the effectiveness of disease-specific therapy compared with placebo, and to no intervention, for the cardiovascular manifestations of Fabry disease. METHODS: Eight databases were searched from inception using a combination of relevant medical subject headings and keywords. Randomised, non-randomised studies with a comparator group and non-randomised studies without a comparator group were included. Studies were screened for eligibility and assessed for bias by two independent authors. The primary outcome comprised clinical cardiovascular events. Secondary outcomes included myocardial histology and measurements of cardiovascular structure, function and tissue characteristics. RESULTS: 72 studies were included, comprising 7 randomised studies of intervention, 16 non-randomised studies of intervention with a comparator group and 49 non-randomised studies of intervention without a comparator group. Randomised studies were not at serious risk of bias, but the others were at serious risk. Studies were highly heterogeneous in their design, outcome measurements and findings, which made assessment of disease-specific therapy effectiveness difficult. CONCLUSION: It remains unclear whether disease-specific therapy sufficiently impacts the cardiovascular manifestations of Fabry disease. Further work, ideally in larger cohorts, with more standardised clinical and phenotypic outcomes, the latter measured using contemporary techniques, are required to fully elucidate the cardiovascular impact of disease-specific therapy. PROSPERO REGISTRATION NUMBER: CRD42022295989.
引用
- Orsborne C, Black N, Naish JH, et al. Disease-specific therapy for the treatment of the cardiovascular manifestations of Fabry disease: a systematic review. Heart. 2023. PMID: 37640453. doi:10.1136/heartjnl-2023-322712
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。